Holen Sie sich die Stockscreener-App
10.01
1.01%
0.10
Handel nachbörslich:
10.00
-0.010
-0.10%
Schlusskurs vom Vortag:
$9.91
Offen:
$10.02
24-Stunden-Volumen:
983.04K
Relative Volume:
1.06
Marktkapitalisierung:
$871.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-106.81M
KGV:
-3.0226
EPS:
-3.3117
Netto-Cashflow:
$-8.40M
1W Leistung:
-4.30%
1M Leistung:
+15.86%
6M Leistung:
-4.03%
1J Leistung:
-26.02%
1-Tages-Spanne:
$9.98
$10.38
1-Wochen-Bereich:
$9.47
$10.75
52-Wochen-Spanne:
$5.1501
$16.73
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
10.01 | 862.62M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Lake Street | Buy |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
Trendlines Converge — Decision Point for Immunome Inc.July 2025 Breakouts & High Accuracy Buy Signal Tips - 선데이타임즈
Multi asset correlation models including Immunome Inc.Quarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - Newser
Short interest data insights for Immunome Inc.Weekly Risk Summary & Daily Profit Focused Screening - Newser
Chart based analysis of Immunome Inc. trendsMarket Activity Report & Low Risk Entry Point Guides - Newser
Will Immunome Inc. bounce back from current support2025 Major Catalysts & Safe Capital Growth Plans - Newser
Is a relief rally coming for Immunome Inc. holdersOptions Play & Low Drawdown Investment Ideas - Newser
Should you hold or exit Immunome Inc. nowTrade Volume Summary & Reliable Volume Spike Trade Alerts - Newser
What’s next for Immunome Inc. stock price [July 2025 Trends]Reliable Volume Spike Alerts - Newser
When is the best time to exit Immunome Inc.Weekly Price Target Forecast and Alerts - Newser
What makes Immunome Inc. stock attractive to long term investorsDaily Pattern Analysis with Return Forecast - Newser
Will Immunome Inc. stock recover after recent dropFree Fundamental Winners With Safe Entry Plan - Newser
Immunome's Undervalued Gamma Secretase Inhibitor Pipeline in Light of SpringWorks' Merck Acquisition - AInvest
Immunome's SpringWorks Buyout Highlights Upside Potential - AInvest
Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha
What makes Immunome Inc. stock price move sharplyReal-Time AI Generated Market Forecast - Newser
Immunome Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Quant Tools Rank Immunome Inc. as High Risk High RewardChart Based Entries - beatles.ru
Wedbush Comments on Immunome’s Q3 Earnings (NASDAQ:IMNM) - Defense World
Research Analysts Offer Predictions for Immunome Q3 Earnings - Defense World
What recovery options are there for Immunome Inc.5-Year Price Trend Summary and Analysis - Newser
How Immunome Inc. stock performs during market volatilityLong-Term Allocation Strategy Summary Breakdown - Newser
What’s next for Immunome Inc. stock priceFree Confirmed Setup With Expert Accuracy - Newser
Is Immunome Inc. benefiting from innovation trendsSmart Portfolio Allocation - newsyoung.net
A Quick Look at Today's Ratings for Immunome(IMNM.US), With a Forecast Between $21 to $38 - 富途牛牛
TD Cowen Maintains Immunome(IMNM.US) With Buy Rating - 富途牛牛
Immunome, Inc. (NASDAQ:IMNM) Revenue Estimates Upgraded by 73% - AInvest
Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance
How to forecast Immunome Inc. trends using time seriesDaily Trade Monitor with Pattern Alerts - Newser
Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of “Buy” by Brokerages - Defense World
Immunome 2025 Q2 Earnings Wider Net Loss Despite Revenue Surge - AInvest
New Product Launches: Will They Boost Immunome Inc. Stock in 2025Growth Focused Entry Plan Suggestions Issued - beatles.ru
JP Morgan Lowers Price Target for Immunome (IMNM) While Maintain - GuruFocus
Immunome 2025 Q2 Earnings Narrowed EPS Loss, 69.8% Revenue Growth - AInvest
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Immunome Advances Cancer Therapy Pipeline Amid Financial Loss - TipRanks
Does Immunome Inc. qualify in momentum factor screeningFree Triple Return Setup with Risk Control - Newser
Immunome earnings beat by $0.12, revenue topped estimates - Investing.com Canada
Immunome’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating - TipRanks
Immunome Q2 Earnings: Revenue $4.01M, Consensus $1.02M; Expects Cash to Fund Operations into 2027 - AInvest
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Immunome Reports Second Quarter 2025 Financial Results and Provi - GuruFocus
Detecting price anomalies in Immunome Inc. with AIFree Weekly Potential Breakout Stock List - Newser
Can Immunome Inc. rally from current levelsStock Entry Point Planner with Volume Spike - Newser
Will Immunome Inc. continue its uptrendStock Market Trend and Pattern Analysis - Newser
What to do if you’re stuck in Immunome Inc.Real Stock Picks With Setup Verification - Newser
What earnings revisions data tells us about Immunome Inc.Trading Volume Spike and Reversal Analysis - Newser
What momentum shifts mean for Immunome Inc.Trade Flow Monitor with Volume Tracker - Newser
Will Immunome Inc. Stock Benefit from AI and Green Energy TrendsLow Risk High Confidence Watchlist Builder - Newser
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):